Driehaus Capital Management LLC Invests $6.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Driehaus Capital Management LLC bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 223,413 shares of the company’s stock, valued at approximately $6,669,000. Driehaus Capital Management LLC owned approximately 0.36% of Kymera Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in Kymera Therapeutics by 18.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after acquiring an additional 996,300 shares in the last quarter. BVF Inc. IL grew its stake in Kymera Therapeutics by 8.9% during the 4th quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock valued at $131,419,000 after acquiring an additional 422,797 shares in the last quarter. Vanguard Group Inc. grew its stake in Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in Kymera Therapeutics by 3.0% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock valued at $156,333,000 after acquiring an additional 113,888 shares in the last quarter. Finally, Artal Group S.A. grew its stake in Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after acquiring an additional 496,400 shares in the last quarter.

Analysts Set New Price Targets

KYMR has been the subject of several research reports. B. Riley upped their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Wells Fargo & Company boosted their target price on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a report on Monday, June 17th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.00.

Kymera Therapeutics Trading Down 1.6 %

Shares of NASDAQ:KYMR opened at $48.69 on Monday. Kymera Therapeutics, Inc. has a 52 week low of $9.60 and a 52 week high of $53.27. The company’s 50 day moving average is $45.79 and its two-hundred day moving average is $39.33. The company has a market cap of $2.99 billion, a PE ratio of -19.40 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. The company had revenue of $25.60 million for the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The company’s quarterly revenue was up 55.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.67) EPS. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.87 EPS for the current year.

Insider Activity at Kymera Therapeutics

In related news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. Insiders have sold 495,605 shares of company stock valued at $19,303,364 in the last ninety days. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.